THE ROLE OF PHARMACOGENETICS IN INDIVIDUAL RESPONSE TO ANTIPARKINSONIAN DRUGS
[ X ]
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
University of Ankara
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: Parkinson’s disease, the second most common neurodegenerative disorder after Alzheimer’s, is a progressive neurodegenerative disease characterized by tremor, rigidity, bradikinesis and postural instability. Environmental and genetic factors contribute to the pathophysiology of this disease. The pioneer of dopamine, L-DOPA, remains the gold standard of pharmacotherapy. Although current therapeutic options are clinically beneficial, since parkinson’s disease is a progressive disorder, all drugs used in treatment decline over time and increase in side effects. Result and Discussion: Recent studies have shown that responses to antiparkinsonian drugs and their side effects exhibit significant interpersonal variability. Pharmacogenetics is a rapidly evolving and very promising field of research aiming to identify genetic markers associated with drug response. Studies in pharmacogenetics have shown that interpersonal genetic differences largely determine the response to drugs used to treat parkinson’s disease. Data obtained in this area will not only have the potential to present valuable therapeutic strategies for antiparkinson treatment, but also increase the probability of successful drug discovery. In this article, compiled studies to identify the role of genetic polymorphisms in better describing the variability in response to antiparkinson therapy and optimizing the pharmacotherapy of parkinson’s disease. © 2022 University of Ankara. All rights reserved.
Açıklama
Anahtar Kelimeler
dopamine, Parkinson's disease, pharmacogenetics, polymorphism
Kaynak
Ankara Universitesi Eczacilik Fakultesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
46
Sayı
2
